NewGenIvf Group Limited approved a reverse stock split of its issued and unissued shares at a ratio of one share for every eight shares, or as otherwise determined by its CEO. No shareholder vote, consent or approval is required or will be sought.
The split takes effect at 12:01 a.m. ET on October 23, 2026, when Class A Ordinary Shares are expected to begin trading on a split-adjusted basis. Based on outstanding Class A Ordinary Shares as of October 21, 2026, the count is expected to decline from approximately 9,821,197 to approximately 1,227,650; the actual count may be greater on the effective date because of convertible note exercises. Holders entitled to a fractional share at the participant level will receive one full post-split share. Options, warrants and other convertible securities will have their exercisable or convertible share counts divided by eight, subject to rounding to the nearest whole share.
NewGenIvf Group Ltd reported unaudited results for the six months ended June 30, 2026, with revenue of $1,924,881, compared with $2,019,628 for the six months ended June 30, 2025. Gross profit was $464,488, compared with $313,804. The company reported a net loss of $8,079,392, versus net income of $698,032; net loss attributable to the company’s shareholders was $8,035,306, compared with net income attributable to shareholders of $724,975.
As of June 30, 2026, cash and cash equivalents were $1,023,789, total assets were $36,436,970 and total liabilities were $10,723,608. Current liabilities totaled $10,508,521, including a $6,881,250 Repurchase Forbearance liability. The balance sheet listed 1,152,607 ordinary shares issued and outstanding as of June 30, 2026, versus 26,736 as of December 31, 2025.
NewGenIvf Group Limited (NIVF) approved a reverse stock split of its issued and unissued shares at a stated ratio of one post-split share for every four shares, or as otherwise determined by its Chief Executive Officer. The split takes effect at 12:01 a.m. ET on October 12, 2026, and Class A ordinary shares will begin split-adjusted trading on the Nasdaq Capital Market at market opening that day. Based on Class A shares outstanding on October 6, the company expects the split to reduce the count from approximately 35,688,329 to approximately 8,922,083; the actual count may be greater on the Record Date due to share issuances from convertible note exercises. No fractional shares will be issued; a holder otherwise entitled to a fraction will receive one full post-split share at the participant level. Options, warrants and other convertible securities outstanding immediately before the split will have their underlying share counts divided by four, subject to rounding to the nearest whole share.
NewGenIvf Group Ltd (NIVF) reported that directors Wing Fung Alfred Siu and Hei Yue Tina Fong each exercised 139,811 post-reverse-split options on October 5, 2026, at US$0.0001 per share; the company issued each director 139,811 Class B ordinary shares. The 279,622 options were exercised in total, and issuance followed settlement through requested debits to the directors’ current accounts and compliance with applicable laws and company policies.
Each director was granted options to acquire 73,647 and 272,140 pre-split Class B shares on July 8 and August 17, 2026, respectively, for no consideration. NewGenIvf effected a 1-for-3 reverse stock split on September 1, 2026. As of October 5, 2026, each reported 292,265 Class B shares beneficially owned with shared voting and dispositive power; the stated holdings consisted of 146,132 shares held by Siu and 146,133 by Fong. Their reported 0.8% was calculated using 35,131,425 Class A and 292,265 Class B shares issued and outstanding as of October 5, 2026. They said they hold the Class B shares to retain control of the issuer.
NewGenIvf Group Ltd (NIVF) Chairman & CEO Wing Fung Alfred Siu exercised vested stock options on October 5, 2026, acquiring 139,811 Class B Ordinary Shares at $0.0001 per share. The options were granted under the issuer’s 2024 Share Incentive Plan and agreements dated July 8 and August 17, 2026. His reported direct holdings after the transaction were 146,132 Class B Ordinary Shares. Reported share amounts reflect two 1-for-3 reverse stock splits implemented on July 6 and September 1, 2026; the post-transaction amount includes 6,321 historically held shares, adjusted from 56,881 pre-split shares.
NewGenIvf Group Ltd (NIVF) Chief Marketing Officer Hei Yue Tina Fong exercised vested stock options on October 5, 2026, acquiring 139,811 Class B Ordinary Shares at an exercise price of $0.0001 per share. Her reported resulting position was 146,133 Class B Ordinary Shares. The share amounts reflect two 1-for-3 reverse stock splits implemented on July 6, 2026, and September 1, 2026.
NewGenIVF Group Limited (NIVF) confirmed it had 27,287,002 issued and outstanding Class A ordinary shares at the close of business on October 1, 2026. The company said the count followed share issuances connected with a best efforts offering announced September 30, 2026, conversions of certain outstanding convertible promissory notes by certain holders, and share issuances under its equity line of credit facility.
NewGenIvf Group Ltd (NIVF) closed a public offering on September 30, 2026, on a reasonable best efforts basis, generating approximately $1.25 million in gross proceeds before placement agent fees and offering expenses. The offering comprised 125,000 Class A ordinary shares and pre-funded warrants to purchase up to 17,732,143 Class A ordinary shares. The price was $0.07 per share and $0.06999 per warrant, with a $0.00001-per-share exercise price.
The pre-funded warrants are immediately exercisable and may be exercised until exercised in full. NewGen expects to use net proceeds, together with existing cash, for investment in K25.ai, restructuring of debt securities, working capital including manufacturing and deployment of Nodexus machines in its cell-sorting business, and general corporate purposes. Aegis Capital Corp. acted as exclusive placement agent; NewGen agreed to pay it a cash fee equal to 8.0% of gross proceeds and reimburse certain expenses. Officers, directors and employees holding ordinary shares agreed, subject to customary exceptions, not to offer, sell or otherwise dispose of beneficially owned ordinary shares for 60 days following closing.
NewGenIvf Group Ltd (NIVF) reported the initial beneficial ownership status of newly appointed independent non-executive director Lau Tsz Hin Vincent on a Form 3. The filing does not report any holdings or transactions in NewGenIvf securities by this director as of the report. The company explains the Form 3 was filed late due to administrative and logistical delays related to remote/foreign notarization and obtaining EDGAR access credentials.
NewGenIvf Group Ltd (NIVF) filed an initial ownership report on Form 3 for Lam Chun Tung Patrick, who serves as an Independent Non-Executive Director. The filing states there are no reportable holdings or transactions in NewGenIvf Group Ltd securities at this time. The company explains the Form 3 was submitted late due to administrative and logistical delays in obtaining remote/foreign notarization and EDGAR access credentials for the newly appointed director, who was appointed on June 8, 2026.